A pioneering medical trial has found that providing pluripotent cells to fetuses affected by spina bifida as part of a surgical repair could constitute a "important advancement" in treating birth defects.
Trial Details and Safety
The US-based trial focused on six unborn babies with the 'open' form of spina bifida. Doctors administered mother's placental stem cells to the surface of the developing neural column during the repair procedure.
Critically, the stem cell application demonstrated a favorable safety profile. Doctors verified that the therapy did not induce cancerous growths, hinder surgical recovery, or block the correction of co-occurring hindbrain herniation.
Promising Outcomes
Imaging conducted after delivery showed a full resolution of brainstem displacement in each of the babies. This favorable anatomical change is closely linked to improved motor skills and quality of life.
"Should it enable additional babies able to walk who wouldn't have, it could establish itself as the new treatment paradigm," said the lead researcher. "The outcomes appear super exciting and create a pathway toward lots of potential new treatments."
Broader Impact and Encouragement
Experts not involved in the trial proposed that additional validation of these observed advantages could announce a "different age" in in-utero treatment. The potential to improve neurological damage present before birth is considered a transformative goal.
Notably important would be advancements for urogenital and gastrointestinal outcomes, which are frequent complications for people affected by this condition.
Future Directions
While this initial trial involved a limited number of patients, its confirmed tolerability and hopeful trends offer a robust platform for expanded clinical research. The integration of stem cell therapy with current in-utero repair procedures presents significant potential for transforming outcomes for future generations with this neural tube defect.